Align Technology, Inc. has announced the appointment of Britt Vitalone, the Executive Vice President and Chief Financial Officer of McKesson Corporation, to its board of directors, along with its audit committee. Vitalone's deep expertise as a business and financial leader in the healthcare industry is expected to be an incredible asset to Align as the company continues to drive growth and innovation globally by delivering digital solutions.
Vitalone, who currently serves as the CFO for McKesson Corporation, is responsible for ensuring that the company’s strategy aligns with shareholder value, communicating the company’s strategies and performance to investors, and implementing a capital structure, financial processes, and controls to support the company’s growth and return on investment goals. In addition to overseeing the accounting, financial planning and analysis, treasury, real estate, investor relations, internal audit, merger & acquisition, and tax functions at McKesson, he also oversees the company’s global procurement and sourcing, corporate security, and McKesson Technology organizations.
With the appointment of Vitalone, Align has increased the size of its board to 11 directors, six of whom have been appointed since 2017.
Align Technology, Inc. designs and manufactures the Invisalign system, the most advanced clear aligner system in the world, as well as iTero intraoral scanners and services, and exocad CAD/CAM software. These technology building blocks enable enhanced digital orthodontic and restorative workflows to improve patient outcomes and practice efficiencies for over 281.4 thousand doctor customers and are key to accessing Align’s 600 million consumer market opportunity worldwide.
Over the past 28 years, Align has helped doctors treat over 20.1 million patients with the Invisalign system and is driving the evolution in digital dentistry through the Align digital platform, the integrated suite of unique, proprietary technologies and services delivered as a seamless, end-to-end solution for patients and consumers, orthodontists and GP dentists, and lab/partners. Today the company's shares have moved 1.39% to a price of $196.98. Check out the company's full 8-K submission here.
